CADL logo

Candel Therapeutics (CADL) Company Overview

Profile

Full Name:

Candel Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 27, 2021

Indexes:

Not included

Description:

Candel Therapeutics is a biotechnology company focused on developing innovative cancer treatments. They use a unique approach that combines gene therapy and immunotherapy to target tumors effectively. Their goal is to improve patient outcomes and provide new options for those battling cancer.

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 26, 25 HC Wainwright & Co.
Buy
Feb 26, 25 Canaccord Genuity
Buy
Feb 20, 25 Citigroup
Buy
Feb 19, 25 Canaccord Genuity
Buy
Feb 7, 25 B of A Securities
Buy
Dec 18, 24 HC Wainwright & Co.
Buy
Nov 18, 24 HC Wainwright & Co.
Buy
Nov 13, 23 HC Wainwright & Co.
Buy
May 22, 23 HC Wainwright & Co.
Buy
May 15, 23 BMO Capital
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Candel Therapeutics?
  • Does Candel Therapeutics pay dividends?
  • What sector is Candel Therapeutics in?
  • What industry is Candel Therapeutics in?
  • What country is Candel Therapeutics based in?
  • When did Candel Therapeutics go public?
  • Is Candel Therapeutics in the S&P 500?
  • Is Candel Therapeutics in the NASDAQ 100?
  • Is Candel Therapeutics in the Dow Jones?
  • When was Candel Therapeutics's last earnings report?
  • When does Candel Therapeutics report earnings?
  • Should I buy Candel Therapeutics stock now?

What is the ticker symbol for Candel Therapeutics?

The ticker symbol for Candel Therapeutics is NASDAQ:CADL

Does Candel Therapeutics pay dividends?

No, Candel Therapeutics does not pay dividends

What sector is Candel Therapeutics in?

Candel Therapeutics is in the Healthcare sector

What industry is Candel Therapeutics in?

Candel Therapeutics is in the Biotechnology industry

What country is Candel Therapeutics based in?

Candel Therapeutics is headquartered in United States

When did Candel Therapeutics go public?

Candel Therapeutics's initial public offering (IPO) was on July 27, 2021

Is Candel Therapeutics in the S&P 500?

No, Candel Therapeutics is not included in the S&P 500 index

Is Candel Therapeutics in the NASDAQ 100?

No, Candel Therapeutics is not included in the NASDAQ 100 index

Is Candel Therapeutics in the Dow Jones?

No, Candel Therapeutics is not included in the Dow Jones index

When was Candel Therapeutics's last earnings report?

Candel Therapeutics's most recent earnings report was on Nov 14, 2024

When does Candel Therapeutics report earnings?

The next expected earnings date for Candel Therapeutics is Mar 28, 2025

Should I buy Candel Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions